TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03830489
Drug: polyethylene glycol plus ascorbic acid
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
Study: NCT03866577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as intravenous infusion
Study: NCT00454337
Drug: FTC/TDF + EFV or LPV/R +T20
Approvals — FDA: no, EMA: no, PMDA: no
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
Study: NCT00454337
Drug: FTC/TDF + EFV or LPV/R
Approvals — FDA: no, EMA: no, PMDA: no
Description: emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
Study: NCT04259164
Drug: QVM149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
Study: NCT04259164
Drug: QMF149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone / Indacaterol
Study: NCT04122300
Drug: Euphrasia Officinalis Preparation
Normalized name: Euphrasia officinalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study: NCT04122300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study: NCT00419991
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
Study: NCT01836471
Drug: Placebo QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Study: NCT04708613
Drug: [C-11]6-OH-BTA-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging of the brain using an amyloid ligand.
Study: NCT04708613
Drug: [F-18]AV-1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging of the brain using a tau ligand.
Study: NCT00826969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03119779
Drug: MTA-Anglus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
Study: NCT03119779
Drug: TheraCal
Normalized name: TheraCal D2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
Study: NCT02105987
Drug: ABC/DTG/3TC FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
Study: NCT02105987
Drug: Ongoing cART regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
Study: NCT00235755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT04967326
Drug: Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04588168
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
Study: NCT00858494
Drug: Hyland's Cold 'n Cough 4 Kids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
Study: NCT01522456
Drug: Retin-A Micro Microsphere 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
Study: NCT05872789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral gel used on tongue and palate twice daily.
Study: NCT02566772
Drug: TAS3681
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
Study: NCT02962648
Drug: Iron isomaltoside/ferric derisomaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Study: NCT05164692
Drug: 0.9% NaCl physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT02291237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match eleclazine administered orally once daily
Study: NCT02890602
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
Study: NCT02279966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01709500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study: NCT04192643
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ML SALİNE SOLUTİON
Study: NCT02353182
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
Study: NCT02047474
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02047474
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01480869
Drug: calcium and cholecalciferol
Normalized name: calcium phosphate / cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
Study: NCT01480869
Drug: calcium and cholecalciferol
Normalized name: calcium phosphate / cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL
Study: NCT01950455
Drug: NAV5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Study: NCT01868802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at 0.9% intravenous infusion will be administered over 40 minutes.
Study: NCT04073537
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib blank analog capsule.
Study: NCT00809562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily for 10 days
Study: NCT00809562
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
Study: NCT00550355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses of Placebo administered over 12 weeks
Study: NCT00616213
Drug: PR104
Normalized name: PR104
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR104 is administered intravenously once every 21 days
Study: NCT04302870
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once daily
Study: NCT02206854
Drug: R-flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg gelatine capsule once orally
Study: NCT02094560
Drug: CAP7.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
Study: NCT00205179
Drug: Novasoy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/day soy isoflavones
Study: NCT00205179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/day matching placebo
Study: NCT00624442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 2 hours
Study: NCT00624442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 24 hours
Study: NCT00624442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion for 72 hours
Study: NCT03760913
Drug: OLP-1002 (Test): Part A, Single Ascending Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
Study: NCT00412646
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03066609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
Study: NCT03006367
Drug: NFC-1 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006367
Drug: NFC-1 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006367
Drug: NFC-1 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006367
Drug: NFC-1 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01595789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
Study: NCT00115089
Drug: R926112
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03032458
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
Study: NCT02477514
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet administered as a single oral dose on Days 3 and 16
Study: NCT00930306
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 doses, Given as Tablet, 2x50 mg
Study: NCT00137098
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00973505
Drug: Aromatase Inhibitor(Femara or Arimidex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
Study: NCT04547764
Drug: triple antibiotic paste (TAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: root canal treatment of pulpally involved teeth.
Study: NCT03809949
Drug: Fentanyl Opioid anesthesia
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
Study: NCT01302600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1ml/kg once a day with food at dinner.
Study: NCT01074359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Study: NCT03282045
Drug: Lysobact Complete Sprey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling spray
Study: NCT03282045
Drug: Tantum Verde® Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling spray
Study: NCT03282045
Drug: Pharyngal® Oromucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling spray
Study: NCT03282045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaling spray
Study: NCT00811941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: as-needed use, tablets, orally, 52 weeks
Study: NCT02061124
Drug: Placebo 1600 mg TID for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04027439
Drug: Part A: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
Study: NCT04027439
Drug: Part B: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
Study: NCT04027439
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Study: NCT03664011
Drug: BI 730357 mixed with [C-14]BI 730357 BS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT04564365
Drug: beta-blocker
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
Study: NCT04354389
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg b.i.d
Study: NCT04354389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: q.d. or b.i.d.
Study: NCT04354389
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg q.d.
Study: NCT00167921
Drug: Premarin® Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00167921
Drug: Premarin® oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03355534
Drug: intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline is given to patients intravenously
Study: NCT00032435
Drug: PAL-40 Active
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00032435
Drug: PAL-40 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00111683
Drug: MK0457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00979459
Drug: MK-1006 DFC
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dry filled capsule contains 20 mg MK-1006
Study: NCT00979459
Drug: MK-1006 FCT
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each film coated tablet contains 40 mg of MK-1006
Study: NCT01782846
Drug: Ixprim®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01782846
Drug: Dafalgan-Codeine®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01262963
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
Study: NCT05047458
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in-capsule (PIC).
Study: NCT05047458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIC.
Study: NCT01812759
Drug: Fentanyl Nasal Spray
Normalized name: Fentanyl Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg nasal spray administered in each nostril.
Study: NCT00360269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 to 100 mg daily
Study: NCT03407144
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
Study: NCT03407144
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study: NCT04174079
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
Study: NCT02359448
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
Study: NCT03528213
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline at physician discretion
Study: NCT01146522
Drug: LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03166085
Drug: PU-H71
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
Study: NCT00890591
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
Study: NCT01664741
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01420497
Drug: intra-articular infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra articular infiltration
Study: NCT04373512
Drug: Culturelle 10 Billion CFU Capsule (2 doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
Study: NCT04373512
Drug: Culturelle 10 Billion CFU Capsule (4 doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
Study: NCT00010088
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00010088
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00635700
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo